share_log

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38

Benzinga ·  Dec 13, 2023 11:48

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $37 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment